Active Implantable Medical Devices Market

Global Active Implantable Medical Devices Market Size (2023 to 2028)

The global active implantable medical devices market size is expected to be growing at a 7.76% CAGR from 2023 to 2028. The market is estimated to be worth USD 38.97 Billion by 2028 from USD 26.82 billion in 2023.

Active implantable medical devices are widely utilized in the medical field for diagnostic and therapeutic purposes, and they are implanted totally or partially in the human body. The device will be implanted in the patient's body and remain there forever. Heart rhythms can be controlled, hypertension can be monitored, functional electrical stimulation of nerves can be provided, glaucoma sensors can be used, and bladder and cranial pressure may be monitored. Many wireless medical devices communicate with receivers in the area that are connected to landlines, cellular networks, or high-speed internet access. Cardiovascular devices, Parkinson's disease, epilepsy, spasticity, and individuals with hearing or vision impairment are among the diseases for which active implanted medical devices are used.

MARKET DRIVERS:

The rising incidence of cardiovascular diseases, increasing aging population, and rising adoption of technological developments primarily drive the global active implantable medical devices market growth.

The growing elderly population is one of the major factors of the globally active implantable medical devices market growth. According to World Health Organization (WHO), the number of people over 65 is supposed to increase from 524 million in 2010 to about 1.5 billion in 2050. By 2050, the global age group over 80 will have 379 million, expected to be 5.5 times the 65 million in 2000. Age is associated with a gradual decline in functional reserve in multiple organ systems, including the heart, brain, and ears. Therefore, it is not surprising that elderly patients use imbalanced medical resources. About 92% of the elderly have at least one chronic illness, and 77% of the elderly have at least two chronic diseases.

Additionally, the emergence of innovative implantable products with enhanced performance and effortless operative procedures is expected to support the market's growth rate during the forecast period. Favorable government policies will likely offer several opportunities to the new and well-established manufacturers in the market. The rising prevalence of cardiovascular diseases and increasing demand for active implantable devices, especially in developing countries, is another promising factor in helping the market reach new heights in growth. Furthermore, an increasing number of medical research activities to create advanced and ergonomically enhanced technologies due to an expanding number of various diseases offer lucrative growth opportunities and push the limits of the global active implantable medical devices market worldwide.

MARKET RESTRAINTS:

Issues related to using such devices, such as those related to device failure and network security, may hinder market growth soon. In addition, the high cost and adverse compensation policies of implantable medical devices are vital challenges and limit the adoption of active implantable medical device solutions in the global market.

COVID-19 Impact on Active Implantable Medical Devices Market:

COVID-19 has affected the Global Economy adversely. The World Health Organization COVID-19 as a public health emergency. Due to its fast spread through human interactions, all countries globally have declared a strict lockdown. The lockdown is the main culprit for the demolition of the global economy. The active implantable medical devices market has been affected negatively during the pandemic. Due to the lockdown, all transportation services were stopped, and the supply chain was disturbed. Moreover, all the hospitals have prioritized COVID-19 patients, where all the other treatment procedures were either canceled or postponed. The non-essential patients have been neglected and postponed their appointments, due to which the market was slowed down during the pandemic. Nevertheless, post-COVID-19, patients are getting treated accordingly, and the active implantable medical devices market is growing. The market players are the primary factor to keep the market into profits post covid.

REPORT COVERAGE:

This research report on the global active implantable medical devices market has been segmented and sub-segmented based on the product and region.

Active Implantable Medical Devices Market – By Product:

• Implantable Cardioverter Defibrillators
  • Transvenous Implantable Cardioverter Defibrillators
    • Biventricular Implantable Cardioverter Defibrillators (ICDs)/Cardiac Resynchronization Therapy Defibrillators (CRT-Ds)
    • Dual-Chamber Implantable Cardioverter Defibrillators
    • Single-Chamber Implantable Cardioverter Defibrillators
  • Subcutaneous Implantable Cardioverter Defibrillator
• Implantable Cardiac Pacemakers
• Ventricular Assist Devices
• Implantable Heart Monitors/Insertable Loop Recorders
• Neurostimulators
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Gastric Electrical Stimulators
• Implantable Hearing Devices
  • Active Hearing Implants
  • Passive Hearing Implants

Based on the product, the Cardioverter defibrillators segment held the largest share in 2022. It is due to increased cardiovascular diseases and high compliance with technologically advanced products.

Another segment that plays a pivotal role in the growth of the global active implantable medical devices market is transvenous implantable cardioverter defibrillators. Over the sub-segments of this type, single-chamber implantable cardioverter defibrillators dominate, followed by subcutaneous implantable cardioverter defibrillators.

The neurostimulators market witnessed the highest growth rate during the forecast period. The demand for neurostimulators, profound brain stimulators, is growing significantly across the globe. In addition, an increase in the prevalence of chronic pain, such as neuropathic pain, pain due to diabetes, arthritis, anxiety, and suffering from an injury, has significantly increased the demand for neurostimulators.

Active Implantable Medical Devices Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Geographically, North America is leading the market with the highest share during the forecast period. The North America Active Implantable Medical Devices Market was sized at USD 7.49 billion in 2020 and is anticipated to reach USD 10.77 billion by 2025 at a CAGR of 7.53% between 2020 to 2025. The rise in the geriatric population and the surge in neurological diseases drive North America's active implantable medical devices market. The United States is leading the North American market in market share. The rise in cardiovascular vascular diseases and the accessibility to technological advancements drive the United States market. For instance, according to the American College of Cardiology, in 2017, more than 800,000 members were dead from cardiovascular disease (CVD) only in the United States.

Moreover, for every 40 seconds, an American will die from CVD, and coronary heart diseases (CHD) like stroke and heart failure account for most CVD deaths. American Heart Association (AHA) estimates that about 5.7 million adults suffer from congestive heart failure in the United States. Moreover, the rise in innovative and technologically advanced products boosts the United States market. Further, Canada is predominantly increasing with the rising healthcare expenditure in this region. These factors led the North American Active Implantable Medical Devices Market during the forecast period.

Europe is the second-largest market in terms of market share. The Europe Active Implantable Medical Devices Market is valued at USD 5.13 billion in 2020. This value is assumed to reach USD 7.49 billion by 2025 to get a 7.86% CAGR during the forecast period. The rise in the older people population and a constant surge in cardiovascular and neurological diseases propel market growth. According to the European Heart Network, over 3.9 million people die from cardiovascular disease (CVD) yearly in Europe, and over 1.8 million deaths in the European Union (EU). Germany and the United Kingdom are the major contributors to the European market. The UK's active implantable medical devices market is witnessed to have robust growth during the forecast period, and the massive availability of advanced technologies in Germany is boosting the market. France is assumed to have a significant growth rate in the market in the future years.

The Asia-Pacific region is expected to grow at the highest CAGR. The Asia-Pacific market was valued at USD 4.28 billion in 2020 and is expected to reach USD 6.43 billion by 2025 at a CAGR of 8.45% during the forecast period. The rise in healthcare spending and the healthcare reforms for infrastructural development are driving the market. The countries like China and India have a huge geriatric populations, and the healthcare infrastructure in these countries is developing every year, thus showing immense healthcare market potential. In addition, the less strict regulations attract pharmaceutical companies to invest in China and India. These factors will boost the Asia Pacific Active Implantable Medical Devices Market in the upcoming years.

KEY MARKET PARTICIPANTS:

Notable companies operating in the global active implantable medical devices market profiled in this report are Medtronic PLC, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova, Cochlear Limited, MED-EL, Sonova Holding AG, William Demant Holding A/S, and Nurotron Biotechnology Co. Ltd.

KEY MARKET HAPPENINGS:

• In May 2019, Medtronic PLC developed the Attain Stability Quad MRI SureScan for active fixation of left heart lead, which has been paired with pacemakers and defibrillators associated with Medtronic’s quadripolar cardiac resynchronization therapy. The device is to attain stability and precision in lead placement, and the product has been approved by the FDA (Food and drug administration in the U.S).
• In Aug 2019, Boston scientific corporation completed the acquisition of BTG Plc, a company that offers a variety of products in streams of specialty pharmaceuticals, cardiovascular, and cancer treatment procedures. The strategic collaboration will enable the Boston Scientific Corporation to provide advanced technologies and improve the infrastructure to support professionals treating severe diseases across the world.
• In Dec 2019, Impulse Dynamics Company developed a device called the Optimizer smart system, which applies to CCM therapy. The FDA has approved the product for treating cardiac dysfunctions in patients. The company has been funded by crucial investors such as Amzek Health Investors, Minth Holdings ltd, Acom biosciences, etc.